Kimberly-Clark
KMB
$109.31
+0.57%
Kimberly-Clark Corp. is a leading global manufacturer of personal care and consumer tissue products, with a portfolio that includes iconic brands such as Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The company also operates a professional segment providing workplace safety and sanitation solutions, and generates over half of its sales in North America. Currently, the stock is in the spotlight due to its planned acquisition of Kenvue's consumer health portfolio, expected to close in the second half of 2026, which could significantly reshape its business mix. Investors are also debating the company's growth prospects amid recent revenue declines and a high dividend yield that has attracted income-focused investors.…
KMB
Kimberly-Clark
$109.31
Related headlines
Investment Opinion: Should I buy KMB Today?
Based on the analysis, KMB is rated a Hold. The stock offers a high dividend yield of 4.94% and trades at a forward PE of 14.73x, which is below the sector average, but the declining revenue and high debt levels temper enthusiasm. The analyst consensus is a 'buy' with an average target of $118.60, implying 7.4% upside, but the wide range of targets ($90-$162) indicates high uncertainty. The thesis is that KMB is a defensive income play with potential upside from the Kenvue acquisition, but the near-term growth challenges warrant caution.
Sign up to view all
KMB 12-Month Price Forecast
The AI assessment is neutral with medium confidence. KMB's high dividend yield and low valuation provide a floor, but the persistent revenue decline and high leverage cap upside. The stock is likely to trade in a range, with the Kenvue acquisition being the key swing factor. If the deal closes and integration goes smoothly, the stock could re-rate higher; if not, it may test the 52-week low. Monitoring quarterly revenue and acquisition progress is essential.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kimberly-Clark's 12-month outlook, with a consensus price target around $118.60 and implied upside of +8.5% versus the current price.
Average Target
$118.60
0 analysts
Implied Upside
+8.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$90 - $162
Analyst target range
The target range is wide, from $90 to $162, indicating high uncertainty about the company's future. The high target assumes successful execution of the Kenvue acquisition, which could drive revenue growth and margin expansion, while the low target prices in potential integration challenges and continued organic sales declines. Recent institutional ratings show no major upgrades or downgrades, with firms like Wells Fargo and UBS maintaining neutral stances, while Piper Sandler and B of A Securities remain overweight/buy. This mixed sentiment suggests analysts are waiting for more clarity on the acquisition's impact before adjusting targets significantly.
Bulls vs Bears: KMB Investment Factors
KMB presents a classic value trap scenario: a high dividend yield and low valuation are offset by declining revenue and high leverage. The bull case rests on the transformative Kenvue acquisition and a potential earnings recovery, while the bear case highlights persistent organic decline and financial fragility. Currently, the bearish evidence is stronger given the consistent revenue drops and negative relative strength. The key tension is whether the Kenvue deal can reverse the top-line decline and justify the current valuation, or if the company's core business continues to erode, making the dividend unsustainable. Investors should monitor the acquisition's progress and quarterly revenue trends closely.
Bullish
- Attractive Dividend Yield: KMB offers a dividend yield of 4.94%, well above the S&P 500 average of ~1.3%. This high yield, supported by a payout ratio of 82%, provides a strong income cushion for investors, especially in a low-yield environment.
- Undervalued on Forward PE: The forward PE of 14.73x is below the sector average of ~18x and the stock's own 5-year average of ~17x. This suggests the market is pricing in limited growth, offering potential upside if the company stabilizes.
- Analyst Consensus Buy: With a consensus rating of 'buy' and an average target price of $118.60, analysts see ~7.4% upside from the current price of $110.39. The high target of $162 implies a 46.8% upside, reflecting optimism about the Kenvue acquisition.
- Strategic Kenvue Acquisition: The planned acquisition of Kenvue's consumer health portfolio, expected to close in H2 2026, could diversify revenue and add high-margin brands. This transformative deal is a key catalyst that could drive long-term growth.
Bearish
- Declining Revenue Trend: Revenue has fallen for four consecutive quarters, with Q1 2026 down 13.99% YoY to $4.163B. This persistent decline indicates weak organic demand and market share losses, challenging the growth narrative.
- High Debt Levels: The debt-to-equity ratio of 4.86 is extremely high, reflecting significant leverage. This increases financial risk, especially if interest rates remain elevated, and could constrain future investments or dividend growth.
- Negative Relative Strength: KMB has underperformed the S&P 500 by 37.6% over the past year, with a 1-year price change of -17.24% vs. +20.37% for the index. This persistent underperformance signals weak investor sentiment and potential further downside.
- High Payout Ratio: The payout ratio of 82% leaves little room for dividend increases or reinvestment. If earnings decline, the dividend could be at risk, which would be a major negative for income-focused investors.
KMB Technical Analysis
Kimberly-Clark's stock has been in a pronounced downtrend over the past year, with a 1-year price change of -17.24%, significantly underperforming the S&P 500's +20.37% gain. The current price of $110.39 sits at 81% of its 52-week range (between $92.42 low and $136.17 high), indicating the stock is closer to its lows than highs, reflecting persistent selling pressure. This positioning suggests the market is pricing in fundamental challenges, though the stock has recovered from its March 2026 low of $93.05, showing some stabilization.
Beta
0.28
0.28x market volatility
Max Drawdown
-32.0%
Largest decline past year
52-Week Range
$92-$134
Price range past year
Annual Return
-17.8%
Cumulative gain past year
| Period | KMB Return | S&P 500 |
|---|---|---|
| 1m | +0.4% | +2.5% |
| 3m | +10.3% | +2.7% |
| 6m | +0.3% | +11.1% |
| 1y | -17.8% | +20.5% |
| ytd | +7.8% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KMB Fundamental Analysis
Revenue has been declining, with the most recent quarter (Q1 2026) showing $4.163 billion, a 13.99% year-over-year decrease from $4.84 billion in Q1 2025. This marks a continuation of a multi-quarter trend: Q2 2025 revenue was $4.163 billion, Q3 2025 was $4.133 billion, and Q4 2025 was $4.08 billion, indicating a consistent slowdown. The decline is broad-based, with segments like diapers ($1.696 billion) and consumer tissue ($1.04 billion) showing softness, though the company is expected to benefit from the Kenvue acquisition in late 2026.
Quarterly Revenue
$4.2B
2026-03
Revenue YoY Growth
-14.0%
YoY Comparison
Gross Margin
36.9%
Latest Quarter
Free Cash Flow
$2.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KMB Overvalued?
Given that net income is positive ($665 million in Q1 2026), the PE ratio is the primary valuation metric. The trailing PE is 16.59x, while the forward PE is 14.73x, suggesting the market expects earnings growth. The gap between trailing and forward PE implies a 12.6% expected earnings increase, which is optimistic given recent revenue declines. The stock's PS ratio of 1.95x is below the sector average of 2.5x, indicating a potential discount, but this is offset by weak growth prospects.
PE
16.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 13x~28x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are elevated due to KMB's high debt-to-equity ratio of 4.86, which indicates significant leverage. This is compounded by a current ratio of 0.75, suggesting potential liquidity concerns. The company's revenue has declined 13.99% YoY in Q1 2026, and with a payout ratio of 82%, there is limited buffer for earnings shocks. If revenue continues to fall, the dividend could be at risk, which would likely trigger a sell-off. Additionally, the negative PEG ratio of -0.84 reflects expected earnings declines, further stressing the financial profile.
FAQ
The key risks include: 1) Financial risk: high debt-to-equity of 4.86 and a current ratio of 0.75, which could lead to liquidity issues. 2) Operational risk: revenue declining 13.99% YoY, indicating weak demand. 3) Dividend risk: payout ratio of 82% leaves little room for error, and a dividend cut is possible if earnings deteriorate. 4) Integration risk: the Kenvue acquisition may face execution challenges, delaying synergies. 5) Macro risk: rising interest rates increase debt costs. The most severe risk is a dividend cut, which could trigger a sell-off and push the stock to the 52-week low of $92.42.
The 12-month forecast is mixed. The bull case (25% probability) targets $130-$162, driven by successful Kenvue integration and revenue recovery. The base case (50% probability) targets $110-$125, assuming stable but modest performance. The bear case (25% probability) targets $90-$100, if revenue declines persist or the dividend is cut. The most likely scenario is the base case, with the stock trading near the analyst average target of $118.60. The key assumption is that the Kenvue acquisition closes and contributes to growth, but without it, the stock may struggle.
KMB appears undervalued relative to its historical valuation and peers. The forward PE of 14.73x is below the sector average of ~18x and the stock's 5-year average of ~17x. The PS ratio of 1.95x is also below the sector average of 2.5x. However, the low valuation reflects the market's concerns about revenue decline and high debt. The PEG ratio is negative, indicating expected earnings declines. The market is pricing in a stagnant or shrinking business, which may be overly pessimistic if the Kenvue acquisition succeeds. Overall, the stock is trading at a discount, but the discount is justified by the risks.
KMB is a good buy for income-focused investors who prioritize dividend yield and stability over growth. The stock offers a 4.94% yield, well above the market average, and trades at a forward PE of 14.73x, which is below the sector average. However, the declining revenue and high debt levels pose risks. The analyst consensus is 'buy' with an average target of $118.60, implying 7.4% upside. The biggest downside risk is a dividend cut if earnings continue to fall. For growth investors, it may not be attractive, but for income investors with a long-term horizon, it could be a solid addition.
KMB is more suitable for long-term investment, given its defensive nature and high dividend yield. The low beta of 0.276 means it is less volatile than the market, making it a stable holding for income investors. The short-term outlook is uncertain due to revenue decline and the pending acquisition, which could cause volatility. For long-term investors, the 4.94% yield provides a solid income stream, and the potential for the Kenvue acquisition to drive growth makes it an attractive hold. A minimum holding period of 3-5 years is recommended to ride out the integration phase and see the benefits of the deal.